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Abstract
Background: Experimental and clinical studies showed that intraoperative infusionof remifentanil
has been associated with postoperative hyperalgesia. Previous reports suggested that spinal N-
methyl-D-aspartate (NMDA) receptors may contribute to the development and maintenance of
opioid-induced hyperalgesia. In the present study, we used a rat model of postoperative pain to
investigate the role of tyrosine phosphorylation of NMDA receptor 2B (NR2B) subunit in spinal
cord in the postoperative hyperalgesia induced by remifentanil and the intervention of
pretreatment with ketamine.
Results: Intraoperative infusion of remifentanil (0.04 mg/kg, subcutaneous) significantly enhanced
mechanical allodynia and thermal hyperalgesia induced by the plantar incision during the
postoperative period (each lasting between 2 h and 48 h), which was attenuated by pretreatment
with ketamine (10 mg/kg, subcutaneous). Correlated with the pain behavior changes,
immunocytochemical and western blotting experiments in our study revealed that there was a
marked increase in NR2B phosphorylation at Tyr1472 in the superficial dorsal horn after
intraoperative infusion of remifentanil, which was attenuated by pretreatment with ketamine.
Conclusions: This study provides direct evidence that tyrosine phosphorylation of the NR2B at
Tyr1472 in spinal dosal horn contributes to postoperative hyperalgesia induced by remifentanil and
supports the potential therapeutic value of ketamine for improving postoperative hyperalgesia
induced by remifentanil.
Background
Numerous experimental and clinical studies have con-
vincingly demonstrated that brief opioid exposure can
enhance pain sensitivity that presents as opioid-induced
hyperalgesia (OIH) [1]. OIH seem to develop more rap-
idly and more frequently with the administration of the
potent, short-acting opioids such as remifentanil than
with longer-acting opioids [2]. Clinically, a relative large
dose of intraoperative remifentanil has been shown to
trigger postoperative secondary hyperalgesia and to
require higher doses of morphine for adequate analgesia
[3]. In a healthy human volunteers study, the authors
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found that a skin area with pre-existing mechanical hyper-
algesia was significantly enlarged after a 60- to 90-min
remifentanil intravenous infusion [4]. Despite extensive
studies in this domain, the possible mechanisms underly-
ing this phenomenon are still unclear.
It is suggested that spinal N-methyl-D-aspartate receptors
(NMDARs) dependent central sensitization, a state that
dorsal horn excitability is increased and its response to
sensory input is facilitated, may be responsible for the
opioid-induced hyperalgesia [5]. Because central sensiti-
zation is considered to reflect the synapses plasticity in
spinal cord, the spinal cord has been the principal focus
for studies of mechanisms of hyperalgesia. Electrophysio-
logical studies using slices of rat spinal cord showed that
both remifentanil per se and glycine contained in the
commercial preparation of remifentanil could elicit rapid
and prolonged up-regulation of NMDA receptor function
[6,7]. Moreover, Clinical research reporting that NMDA
receptor antagonists such as ketamine have the ability to
inhibit hyperalgesia induced by remifentanil has also sug-
gested a possible implication of NMDA receptor in the
phenomena mentioned above [3].
NMDARs are heteromultimeric complexes that are com-
prised of at least two types of subunits, the principal sub-
unit NR1 and the modulatory subunit NR2A-D [8].
Particularly crucial are the NMDAR 2B (NR2B) subunit, it
has an important function in spinal dorsal horn sensory
pathways [9]. Our previous studies have shown that NR2B
play an important role in the development of neuropathic
pain and cancer pain [10,11]. Protein tyrosine phosphor-
ylation regulates NMDA channel receptor activity. The
NR2B receptor has been identified as major tyrosine phos-
phorylated protein in the postsynaptic density and plays a
key role in the signal transduction pathways for NMDA
receptor activation [12]. It has been reported that tyrosine
phosphorylation of the NR2B subunit plays a role in the
induction of long-term potentiation (LTP), a phenome-
non related to central sensitization [13,14]. In addition,
tyrosine phosphorylation of the NR2B subunit in the rat
spinal dorsal horn is closely related to the initiation and
development of inflammatory hyperalgesia [15]. These
studies suggested an implication of tyrosine phosphoryla-
tion of NR2B in the enhancement of synaptic efficacy and
thus the development of central sensitization. However,
there have been no reports on whether tyrosine phospho-
rylation of NR2B is associated with the postoperative
hyperalgesia induced by remifentanil.
Ketamine, a noncompetitive NMDA receptor antagonist,
is a widely used general anesthetic because of its analgesic
effects. Although ketamine acts on a variety of receptors,
the analgesic effect of ketamine mainly stem from its
NMDA-receptor antagonistic properties through preven-
tion of central sensitization [16]. Ketamine inhibits the
NMDA receptor by two distinct mechanisms: (1) Keta-
mine blocks the open channel and thereby reduces chan-
nel mean open time, and (2) ketamine decreases the
frequency of channel opening by an allosteric mechanism
[17]. Therefore it is routinely served as a useful tool to
study the role of NMDA receptor in a wide variety of ani-
mal and human models. In previous studies, subcutane-
ous pretreatment with ketamine 10 mg/kg completely
prevented the development of long-lasting hyperalgesia
after systemic opioid administration in rats [18,19], as
well as long-lasting hyperalgesia induced by intrathecal
morphine in rats [20].
According to the scenario mentioned above, we hypothe-
sized that tyrosine phosphorylation of the NR2B subunit
in spinal cord would contribute to the hyperalgesia
induced by remifentanil, which may be prevented by pre-
treatment with ketamine. In a rat model of postoperative
pain, using immunohistochemistry and immunoblotting,
we tested this hypothesis through examining tyrosine
phosphorylation of NR2B subunit at Tyr1472 in the
superficial spinal cord after intraoperative infusion of
remifentanil with or without pretreatment of ketamine.
Methods
Animals
Experiments were performed on adult male Sprague-Daw-
ley rats (weighing 220-250 g, obtained from the Labora-
tory Animal Center of Drum Tower Hospital). Animals
were housed in groups of four per cage with a 12-h light-
12-h dark cycle (lights on at 7:00 AM) at a constant room
temperature of 22 ± 2°C. The animals had access to food
and water ad libitum. All experiments were approved by
our Institutional Animal Care and Use Committee and
conform to the guidelines for the use of laboratory ani-
mals [21]. Every effort was made to minimize animal suf-
fering and to use the minimum number of animals
necessary to obtain valid results.
Drugs
Remifentanil hydrochloride (batch number: 081101, Ren
Fu Co, China), ketamine hydrochloride (batch number:
KH080601, Heng Rui Co, China), sevoflurane (batch
number: 08100931, Heng Rui Co, China). Ketamine (10
mg/kg) was dissolved in saline (NaCl 0.9%) to a volume
of 0.1 ml. Remifentanil (0.04 mg/kg) was dissolved in
saline (NaCl 0.9%) to a volume of 0.4 ml. Subcutaneous
ketamine injection (10 mg/kg, 0.1 ml) was performed 30
min before plantar incision. Remifentanil (0.04 mg/kg,
0.4 ml) was infused subcutaneously over a period of 30
min using an apparatus pump. The infusion rate was 0.8
ml/h. Control animals received the same volume of saline
in identical conditions.Molecular Pain 2009, 5:76 http://www.molecularpain.com/content/5/1/76
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Surgical procedure
The incisional surgery was based on the procedure
described by Brennan et al [22]. Rats were anesthetized
with sevoflurane (induction, 3%; surgery, 1%) via a nose
mask. The plantar aspect of right hind paw was prepared
in a sterile manner with 5% povidone-iodine solution,
and the foot was placed through a hole in a sterile drape.
A longitudinal 1-cm incision was made through the skin
and fascia, starting at 0.5 cm from the edge of the heel and
extending toward the toes of the right hind paw. The
plantaris muscle was elevated using forceps and incised
longitudinally, leaving the muscle origin and insertion
intact. After hemostasis with gentle pressure, the skin was
closed with two mattress sutures of 5-0 nylon. The wound
site was covered with aureomycin ointment.
Behavioral testing
To evaluate mechanical hyperalgesia, paw withdrawal
mechanical thresholds (PWMT) were determined by
using calibrated von Frey filaments (2-15 g bending force;
Stoelting Co). Rats were placed individually in a cage (22
cm × 12 cm × 12 cm) with a wire mesh bottom (1 cm × 1
cm). Each von Frey filament was applied vertically to an
area adjacent to the wound for six seconds while the fila-
ment was gently bent. The test was repeated five times
with a five-minute test-free period between withdrawal
responses. A positive response was defined as complete
lifting of the hind paw off the surface of the cage or flinch-
ing. The PWMT was determined by the "up-and-down"
method and the data were analyzed using the nonpara-
metric method of Dixon, as described by Chaplan et al
[23].
To evaluate thermal hyperalgesia, paw withdrawal ther-
mal latency (PWTL) was measured by using testing equip-
ment (BME410A, Institute of Biological Medicine,
Academy of Medical Science, China). Rats were placed in
a clear plastic chamber (22 cm × 12 cm × 12 cm) with a
glass floor (2 mm thick). A radiant heat source was posi-
tioned under the glass floor and focused on the plantar
surface adjacent to the wound of right hind paw. The
withdrawal latency to the thermal stimulation was
defined as the time from onset of radiant heat to with-
drawal of the rat hind paw. A cutoff time of 25 s was estab-
lished to prevent tissue damage. There were five trials per
rat, taken at 5 min intervals. The mean PWTL equal to the
average of the latter three stimuli.
Experimental Protocol and Groups of Experiments
All rats were anesthetized with sevoflurane (induction,
3%; surgery, 1%) via a nose mask during 30 min. We per-
formed the experiments using five groups of rats (n = 12):
group C (rats underwent a sham procedure that consisted
of the administration of sevoflurane and the same volume
of saline without incision); group I (rats underwent a sur-
gical incision and the same volume of saline); group K
(subcutaneous injection of ketamine 30 min before
plantar incision); group R (rats underwent a surgical inci-
sion and remifentanil was infused subcutaneously at the
moment of surgical incision over a period of 30 min);
group K+R (subcutaneous injection of ketamine 30 min
before plantar incision in remifentanil-treated rats).
After arrival, animals were left to become accustomed to
the animal care unit for 5 days. For 2 weeks before the
experiments, the animals were weighed daily, handled
gently during 5 min, and placed in the test room for 2 h
(from 9:00 AM to 11:00 AM), where they were left to
become accustomed to the various apparatuses. All exper-
iments were performed by the same investigator in a quiet
test room close to the storage room. All experiments
began at 9:00 AM and were performed on groups of 12
animals during the light part of the cycle.
For the von Frey and plantar tests, the animals were famil-
iarized with the special conditions of evaluation in the
absence of nociceptive stimulation. After the habituation
period, baseline responses were obtained just one day
before surgery. The experiments (incision + administra-
tion of drugs) were performed 1 day later according to the
protocol described above. PWMT and PWTL tests were
performed at 2 h, 6 h, 24 h, and 48 h after the surgical pro-
cedure. The specimens for Immunohistochemical staining
and Western blot analysis were collected just after behav-
ioral testings at 48 h.
Immunohistochemistry
While under deep anesthesia (5% sevoflurane), rats were
perfused transcardially with saline, followed by freshly
prepared 4% paraformaldehyde in 0.1 M phosphate
buffer saline (PBS, pH = 7.4). The lumbosacral spinal cord
was dissected out, postfixed in the same fixative at 4°C
overnight and then followed by paraffin wax imbedding.
Transverse sections (4 μm) were cut through the lumbar
L4-5spinal cord by a paraffin slicing machine. Paraffin
sections were dewaxed in xylene and rehydrated through
graded ethanol dilutions. Endogenous peroxidase activity
was inhibited by incubation of slides in 3% hydrogen per-
oxide solution at room temperature for 30 minutes, fol-
lowed by three washes 5 minutes in PBS. Next, slides were
incubated with 20% normal goat serum for 30 minutes at
room temperature and then were diluted with primary
antibody (phospho-Tyr1472 NR2B, 1:1000, abcam, Bio-
technology, English) at 4°C for 24 h. Sections were then
washed 5 minutes in PBS three times, followed by incuba-
tion with goat anti-rabbit serum (1:200) for 30 minutes at
room temperature followed by three washes 5 minutes in
PBS. Antibody localization was detected by addition of
the DAB chromogen for 1-5 minutes until staining was
visible, followed by washing with PBS/water. Slides wereMolecular Pain 2009, 5:76 http://www.molecularpain.com/content/5/1/76
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counterstained with Haematoxylin, dehydrated with
graded ethanols and covered with gelatin. Slides were
observed with an Olympus optic microscope equipped
with an Olympus DP11 camera and analysed on-line
using Image Pro Plus software (Media Cybernetics, Silver
Spring, MD, USA). Each group using six rats and six sec-
tions randomly selected from each animal. For each rat,
the mean optical density of NR2B tyrosine phosphoryla-
tion was obtained by averaging the values from six sec-
tions.
Western Blotting
While under deep anesthesia (5% sevoflurane), the right
dorsal horn of the spinal cord L4-L5 segments were
removed rapidly and stored in liquid nitrogen. Tissue
samples were homogenized in lysis buffer. The homoge-
nate was centrifuged at 13,000 rpm for 10 min at 4°C and
supernatant was removed. The protein concentration was
determined using Bradford method, a detergent-compati-
ble protein assay with a bovine serum albumin as stand-
ard. Samples (70 μg) were separated on SDS-PAGE (6%)
and transferred onto a nitrocellulose membrane. The filter
membranes were blocked with 5% nonfat milk for 1 h at
room temperature andincubated with the primary anti-
body (phosphor -Tyr 1472 NR2B, 1:500, CST, Biotechnol-
ogy, USA). The membrane was washed with TBST buffer
and incubated for 1 h with the secondary antibody conju-
gated with horseradish peroxidase (1:5000; Jackson
ImmunoResearch, USA) for 1 h at room temperature and
visualized in ECl solution for 1 min followed by film
exposure for1-10 min. The loading and blotting of equal
amount of proteins were verified by reprobing the mem-
brane with antibody against β-actin (1:10,000, Santa
Cruz, Biotechnology, USA). The density of specific bands
was measured with a computer-assisted imaging analysis
system (IPLab software, Scanalytics, Fairfax, VA).
Statistical Analysis
Data were expressed as the mean ± SD. Repeated measures
ANOVA was performed to determine overall differences at
each time point in PWMT and PWTL. A one-way ANOVA
was used to determine differences in the expression of
tyrosine phosphorylation of NR2B across all experiment
groups. Post hoc analysis was performed using the LSD
test for multiple comparisons in order to determine the
differences among experiment groups. The statistical sig-
nificance criterion was P < 0.05.
Results
Effects of intraoperative remifentanil infusion on PWMT 
and PWTL during the postoperative period and the 
intervention of pretreatment with ketamine
When compared with baseline, the administration of
sevoflurane and the subcutaneous infusion of saline for a
period of 30 min to rats in the absence of surgery did not
produce significant changes of PWMT and PWTL (P  >
0.05). However, decreases in nociceptive thresholds were
observed in other groups from 2 h to 48 h after the sur-
gery. Compared with baseline and group C, the plantar
incision induced a decrease in PWMT (P  < 0.01) and
PWTL (P < 0.01) in the operated paw during the postop-
erative period (each lasting between 2 h and 48 h). No sta-
tistically significant differences in nociceptive thresholds
were observed between group K and group I (P > 0.05).
Intraoperative infusion of remifentanil significantly
enhanced mechanical allodynia and thermal hyperalgesia
induced by the plantar incision. This was manifested by a
significant decrease in PWMT (P < 0.01) and PWTL(P <
0.05) below those observed in rats treated with saline in
the presence of surgery. Nevertheless, pretreatment with
ketamine strongly reduced the enhancement of mechani-
cal allodynia (P < 0.01) and thermal hyperalgesia (P <
0.01) induced by perioperative remifentanil administra-
tion (Figure 1 and Figure 2).
Immunocytochemical localization and expression of NR2B 
phosphorylation at Tyr-1472 in spinal cord
To localize and assess the expression of NR2B phosphor-
ylation at Tyr-1472 in the spinal cord during the mainte-
Effects of remifentanil on PWMT during the postoperative  period and the intervention of ketamine Figure 1
Effects of remifentanil on PWMT during the postop-
erative period and the intervention of ketamine. Ket-
amine (10 mg/kg, 0.1 ml) or saline was subcutaneously 
injected 30 min before surgery. Under sevoflurane anesthe-
sia, remifentanil (0.04 mg/kg, 0.4 ml) or saline was subcutane-
ously infused in the absence or presence of the right hind 
paw incision during a period of 30 min. PWMT was evaluated 
at 24 h before incision and at 2 h, 6 h, 24 h and 48 h after 
surgery. Number of rats per group was twelve. Data are 
expressed as means ± SD. *P < 0.01 vs baseline, # P < 0.01 vs 
group C, ЌP < 0.01 vs group I, P < 0.01 vs group R.Molecular Pain 2009, 5:76 http://www.molecularpain.com/content/5/1/76
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nance of hyperalgesia induced by remifentanil,
immunohistochemical studies were performed. Typical
photomicrographs showed that the immunohistochemi-
cal location of the phosphorylation NR2B subunit was in
the superficial dorsal horn (Laminae I-II) at the L4-L5 spi-
nal cord, ipsilateral to the incision (Figure 3). The mean
optical density of NR2B tyrosine phosphorylation in the
superficial dorsal horn was summarized in Figure 4. The
expression of NR2B tyrosine phosphorylation in the
superficial dorsal horn was weak in rats receiving sevoflu-
rane and saline without surgery. The expression of NR2B
tyrosine phosphorylation in the superficial dorsal horn of
the group I, K, R, K+R was increased when compared to
group C (P  < 0.01). No significant change was found
between group I and group K(P > 0.05). Intraoperative
infusion of remifentanil significantly enhanced the
expression of NR2B tyrosine phosphorylation in the
superficial dorsal horn of spinal cord(P  < 0.05). Con-
versely, pretreated ketamine decreased the higher level of
NR2B tyrosine phosphorylation in spinal dorsal horn
caused by intraoperative infusion of remifentanil (P  <
0.05).
Western Blot Analysis
To quantificate the expression of NR2B phosphorylation
at Tyr-1472 in the dorsal horn during the maintenance of
hyperalgesia induced by remifentanil, western blot stud-
ies were performed. When compared with rats receiving
sevoflurane and saline in the absence of surgery, the right
hind paw plantar incision increased the level of NR2B
Effects of remifentanil on PWTL during the postoperative  period and the intervention of ketamine Figure 2
Effects of remifentanil on PWTL during the postop-
erative period and the intervention of ketamine. Ket-
amine (10 mg/kg, 0.1 ml) or saline was subcutaneously 
injected 30 min before surgery. Under sevoflurane anesthe-
sia, remifentanil (0.04 mg/kg, 0.4 ml) or saline was subcutane-
ously infused in the absence or presence of the right hind 
paw incision during a period of 30 min. PWTL was evaluated 
at 24 h before incision and at 2 h, 6 h, 24 h and 48 h after 
surgery. Number of rats per group was twelve. Data are 
expressed as means ± SD. * P < 0.01 vs baseline, # P <0.01 vs 
group C, ЌP <0.05 vs group I, P < 0.01 vs group R.
Typical photomicrographs representing tyrosine phosphor- ylation of NR2B immunoreactive neurons in the superficial  dorsal horn Figure 3
Typical photomicrographs representing tyrosine 
phosphorylation of NR2B immunoreactive neurons 
in the superficial dorsal horn. The L4-L5 spinal cords for 
analysis were collected at 48 h after the surgery. In prepara-
tions of control group, hardly any tyrosine phosphorylation 
of NR2B immunoreactive neurons was found in the dorsal 
horn region (A). In preparations of rats with incision receiv-
ing saline or ketamine, moderate tyrosine phosphorylation of 
NR2B immunoreactive neurons was obtained in the superfi-
cial dorsal horn (Laminae I-II) at the L4-L5 spinal cord, ipsilat-
eral to the incision (B and C). The number of tyrosine 
phosphorylation of NR2B immunoreactive neurons were 
drastically upregulated in rats receiving infusion of remifen-
tanil (D), which was remarkably inhibited by pretreatment 
with ketamine (E). Magnification: × 100. Scale bar = 100 μm.Molecular Pain 2009, 5:76 http://www.molecularpain.com/content/5/1/76
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tyrosine phosphorylation in the spinal dorsal cord (P <
0.01). No significant change was found between group I
and group K (P > 0.05). The expression of NR2B tyrosine
phosphorylation in rats receiving intraoperative remifen-
tanil infusion was significantly upregulated when com-
pared with rats receiving intraoperative saline infusion (P
< 0.01). Conversely, pretreatment of ketamine decreased
the higher level of NR2B tyrosine phosphorylation in spi-
nal dorsal horn caused by remifentanil (P < 0.01) (Figure
5).
Discussion
There are two main findings in this study. The first one is
that hyperalgesia induced by remifentanil in a rat model
of postoperative pain associated with an enhancement of
tyrosine phosphorylation of NR2B in superficial spinal
cord. The second finding is that pretreatment with keta-
mine, via inhibiting tyrosine phosphorylation of NR2B in
superficial spinal cord of rats, attenuated exaggerated
hyperalgesia induced by remifentanil.
It has been reported that a relatively large dose of intraop-
erative remifentanil triggers postoperative secondary
hyperalgesia in humans. However, it is difficult to discern
pain due to tissue damage from hyperalgesia stem from
both nociceptive inputs and remifentanil during the post-
operative period in clinical studies. So it would be an
effective method that using a rat model of postoperative
pain to investigate the mechanism of the remifentanil-
induced hyperalgesia. In this model, we imitated the
administration of general anesthesia in humans which
including inhalation of sevoflurane and subcutaneous
infusion of remifentanil at constant speed. The doses of
remifentanil (0.04 mg/kg) in our study were selected
according to literature in rats showing that administration
of remifentanil produces a loss of righting reflex that is
predictive of clinical anesthesia [24]. In the present study
we observed that the infusion of remifentanil during sur-
gery produced rapid and prolonged mechanical allodynia
and thermal hyperalgesia during the postoperative period
for up to 2 days. The results are consistent with Celerier's
Immunohistochemical analysis Figure 4
Immunohistochemical analysis. The L4-L5 spinal cords 
for analysis were collected at 48 h after the surgery. The 
mean optical density of NR2B tyrosine phosphorylation (py-
NR2B) in the superficial dorsal horn (Laminae I-II) at the L4-
L5 spinal cord are summarized. Data from five groups, each 
using six rats. For each rat, the mean optical density of NR2B 
tyrosine phosphorylation was obtained by averaging the val-
ues from six sections. Data are expressed as means ± SD. * P 
< 0.01 vs group C, # P < 0.05 vs group I, P < 0.05 vs group 
R.
The expression level of tyrosine phosphorylation of NR2B in  superficial spinal cord in each group Figure 5
The expression level of tyrosine phosphorylation of 
NR2B in superficial spinal cord in each group. The L4-
L5 spinal cords for analysis were collected at 48 h after the 
surgery. Proteins were extracted from the dorsal half of the 
L4-L5 spinal cord.(A) Representative western blot for tyro-
sine phosphorylation of NR2B (py-NR2B) in the superficial 
dorsal horn at the L4-L5 spinal cord; (B) quantification of 
NR2B tyrosine phosphorylation in each group. Data from 
five groups, each using six rats. Data are expressed as means 
± SD.* P < 0.01 vs group C, # P < 0.01 vs group I, P < 0.01 
vs group R.Molecular Pain 2009, 5:76 http://www.molecularpain.com/content/5/1/76
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study showing that intraoperative subcutaneous infusion
of remifentanil in a mice model of postoperative pain
enhances the mechanical allodynia and thermal hyperal-
gesia (each lasting between 2 and 7 days) resulting from
surgical incision [25].
Accumulated evidences have indicated that activation of
NMDA receptor play a key role in the development and
maintenance of central sensitization states underlying the
behavioral manifestations of hyperalgesia [26]. Once cen-
tral sensitization is established, it does not require ongo-
ing peripheral inputs from the injured tissue and then
constitute a pathophysiologic mechanism underlying
pain hypersensitivity states [27]. Protein phosphorylation
is important for the up-regulation of NMDAR function.
NR2 is tyrosine phosphorylated at its C-terminal tails by
Src-family tyrosine kinases, such as Src, Fyn [28,29].
Although both NR2A and NR2B subunits can be tyrosine
phosphorylated in vitro, studies have showed that tyro-
sine phosphorylation of the NR2B subunits play a key role
in the NMDA receptor activation, and contribute to noci-
ceptor activity induced spinal plasticity and the develop-
ment of central sensitization [30]. The NR2B subunit
contains a number of potential tyrosine phosphorylation
sites in the cytoplasmic C-terminal tails. Among those
tyrosines, Tyr-1472 appears to be the major Fyn-mediated
phosphorylation site. Tyr-1472 phosphorylation is
important for synaptic plasticity and plays a role in the
induction of LTP [31], which shares pharmacology and
signal transduction pathways with OIH [32]. It has been
reported that tyrosine phosphorylation of the NR2B at
Tyr1472 in the spinal dorsal horn contribute to the devel-
opment of hyperalgesia in inflammation pain model, as
well as neuropathic pain model [30,33]. Moreover, sug-
gestion that the mechanisms of central sensitization
induced by opiates share some common pathways with
those induced by nociceptive inputs [34] led us to specu-
late that tyrosine phosphorylation of the NR2B subunit at
Tyr1472 in spinal cord may be involved in the hyperalge-
sia induced by remifentanil.
This hypothesis is supported by immunohistochemical
and westernblotting experiments in our study showing
that remifentanil significantly increased the expression of
tyrosine phosphorylation of NR2B in the lamina I-II of
the L4-L5 spinal cord. So the activation of NMDARs posi-
tively correlates with phosphorylation of NR2B at Y1472
may be a component of underlying mechanisms of hyper-
algesia induced by remifentanil. Moreover, because
NMDA receptors are activated by the co-agonists gluta-
mate and glycine [35], the role of glycine contained in the
commercial preparation of remifentanil cannot be
excluded. Our study reports for the first time in an vivo
model of hyperalgesia induced by remifentanil that tyro-
sine phosphorylation of NR2B at Tyr1472 in spinal dorsal
horn plays a key role in hyperalgesia induced by remifen-
tanil. Although in our study we cannot confirm the precise
mechanisms, we hope our results could provide clue to
further explore the possible mechanisms regarding its sig-
naling pathways in the spinal cord after administration of
remifentanil.
Of note is our finding that subcutaneous pretreatment
with ketamine 10 mg/kg could prevent the development
of mechanical allodynia and thermal hyperalgesia
induced by remifentanil and the effects are long lasting.
Although at present considerable controversy exists
regarding the effects of ketamine on the hyperalgesia
induced by remifentanil in humans [3,36], our result is
consistent with most clinical reports suggesting that keta-
mine pretreatment could prevent such a hyperalgesia
induced by remifentanil. Interestingly, we observed that
pretreatment with ketamine 10 mg/kg had no effect on
the nociceptive threshold if administered alone, but it pre-
vented the delayed hyperalgesia induced by remifentanil
for two days, meaning the preventive effects of this dose
of ketamine on hyperalgesia mainly stem from its antihy-
peralgesia properties, but not antinociceptive effects.
Correlated with the antihyperalgesic and antiallodynic
effects of ketamine, in the present study immunocyto-
chemical and western blotting experiment revealed pre-
treatment with ketamine 10 mg/kg reduced the higher
level of NR2B tyrosine phosphorylation in spinal dorsal
horn caused by remifentanil. Wilson's study showed that
the increased expression of NR2B in the superficial dorsal
horn of animal models of neuropathic pain was attenu-
ated following NMDA receptor antagonist pretreatment
[37]. Furthermore, there were studies observed that
increased NR2B tyrosine phosphorylation after LTP could
blocked by MK-801 (an NMDAR channel blocker), sug-
gesting that tyrosine phosphorylation of NR2B is triggered
by activation of the NMDAR itself [13,14]. Collectively,
these studies in combination with our current data would
argue that the antihyperalgesic and antiallodynic effect of
ketamine may be linked, at least partially or indirectly, to
its ability to inhibit tyrosine phosphorylation of NR2B in
the spinal dorsal horn. Additionally, other factors such as
blocking voltage-dependent calcium channel [38,39],
inhibition of NO synthase [40] and involvement of opiate
and monoaminergic neuronal systems [41,42] cannot be
excluded at present, which requires additional investiga-
tion.
Conclusions
This study showed that the expression of NR2B tyrosine
phosphorylation in the spinal dorsal horn increases mark-
edly during the maintenance of the hyreralgesia induced
by remifentanil and this increase can be prevented by pre-
treatment with ketamine. In summary, the present inves-Molecular Pain 2009, 5:76 http://www.molecularpain.com/content/5/1/76
Page 8 of 9
(page number not for citation purposes)
tigation provides evidence for the significant role of NR2B
tyrosine phosphorylation in spinal cord in the mainte-
nance of hyreralgesia induced by remifentanil. In addi-
tion, this study supports the potential therapeutic value of
ketamine for the prevention of this phenomenon and fur-
ther suggests that the NR2B-selective antagonist hold
promise as novel therapeutics for the control of remifen-
tanil induced hyperalgesia.
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